HK Stock Market Move | INNOVENT BIO (01801) plunges over 14% in the afternoon, National Biopharmaceutical Alliance to begin centralized procurement, Bevacizumab Monoclonal Antibody and other varieties may be included.

INNOVENT BIO (01801) plummeted more than 14% in the afternoon, falling 7.62% to HK$30.9 with a trading volume of HK$8.53 billion as of press time. On the news front, on January 14, the Anhui Provincial Medical Insurance Work Conference was held in Hefei, which deployed the Anhui Provincial Medical Insurance work for 2025 in seven aspects. The third point mentioned leading the national alliance for the centralized procurement of biologics. According to institutions, this national alliance for the centralized procurement of biologics may include multiple varieties such as Bevacizumab Injection, Rituximab Injection, and Adalimumab Injection. Morgan Stanley published a research report in December last year, stating that based on INNOVENT BIO's first half and third quarter product revenue performance, the annual growth forecast for the core product, Tyvyt (Envafolimab), has been raised from 15% to 40%. The growth forecast for a series of biosimilar products such as Rituximab, Adalimumab, and Bevacizumab have also been adjusted upwards, with corresponding forecasts of R&D and sales costs expected to increase accordingly.